BLA submitted to US FDA Seeking Approval for Ivonescimab + chemo Combo in 2L+ EGFRm NSCLC January 18, 2026
FDA Alignment Received on Registrational Studies Design for NDV-01 for 2L refractory high-grade NMIBC and in intermediate-risk NMIBC in the adjuvant setting January 18, 2026
IND application submitted for GTB-5550 TriKE for B7-H3 expressing solid tumor cancers January 18, 2026
